0001209191-18-011372.txt : 20180220 0001209191-18-011372.hdr.sgml : 20180220 20180220164308 ACCESSION NUMBER: 0001209191-18-011372 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180215 FILED AS OF DATE: 20180220 DATE AS OF CHANGE: 20180220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Menzaghi Frederique Ph.D. CENTRAL INDEX KEY: 0001597152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 18625302 MAIL ADDRESS: STREET 1: C/O CARA THERAPEUTICS, INC. STREET 2: 1 PARROTT DRIVE CITY: SHELTON STATE: CT ZIP: 06484 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-15 0 0001346830 Cara Therapeutics, Inc. CARA 0001597152 Menzaghi Frederique Ph.D. C/O CARA THERAPEUTICS, INC. 107 ELM STREET, 9TH FLOOR STAMFORD CT 06902 0 1 0 0 Sr VP-Research & Development Common Stock 2018-02-15 4 S 0 3000 15.02 D 119000 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. /s/Darren DeStefano, Attorney-in-Fact 2018-02-20